[The therapeutic action of recombinant human interleukin-2 (IL-2) in experimental acute radiation sickness].
In experiments with CBA mice and non-purebred dogs the pronounced medicinal effect was found. Injections of IL-2 had been going 3 times per day for 5 days beginning with 6 h after exposure. The optimum doses of IL-2 were 20.10(3) U/kg day for mice and 3.10(3) U/kg day for dogs. By this scheme of IL-2 application the survival of mice exposed to LD75 and LD90 and dogs exposed to LD86 raised up to 100%, 70% and 70%, respectively.
Rogacheva
S A
SA
D000208:Acute Disease; D000818:Animals; D001853:Bone Marrow / Q000473:pathology / Q000528:radiation effects; D016009:Chi-Square Distribution; D003114:Colony-Forming Units Assay; D004285:Dogs; D004307:Dose-Response Relationship, Radiation; D004353:Drug Evaluation, Preclinical; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use*; D008297:Male; D051379:Mice; D008808:Mice, Inbred CBA; D011833:Radiation Injuries, Experimental / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use; D013997:Time Factors
D007376:Interleukin-2; D011994:Recombinant Proteins
Lechebnoe deĭstvie rekombinantnogo interleĭkina-2 (IL-2) cheloveka pri ostroĭ luchevoĭ bolezni v éksperimente.